Verigraft's P-TEV: Advancing Personalized Regenerative Therapy for CVI
March 27, 2026, 10:05 am
Location: United States, Pennsylvania, Allentown
Employees: 10001+
Founded date: 1899
Verigraft launches pivotal Phase II/III trials for P-TEV, a personalized biological therapy. It targets Chronic Venous Insufficiency (CVI), a widespread vascular disease lacking curative treatment. P-TEV replaces diseased veins, ending lifelong immunosuppression. A recent $10 million investment backs this push for US and European market approval by 2028. This marks a significant leap in regenerative medicine.
Verigraft, a pioneering Swedish biotechnology company, pushes the boundaries of personalized medicine. Its innovative approach targets serious vascular conditions. The company just initiated a pivotal Phase II/III clinical trial. This trial focuses on Chronic Venous Insufficiency, or CVI. It represents a significant step for patients globally.
The core of Verigraft's innovation is P-TEV. This stands for Personalized Tissue-Engineered Vein. P-TEV offers a fully biological transplant. It replaces damaged vein segments. The technology removes the need for lifelong immunosuppression. This factor greatly improves patient recovery. It enhances overall quality of life. The process is scalable. Manufacturing completes within ten days. This makes it clinically feasible for wide application. Ninety-two granted patents protect this groundbreaking method.
Chronic Venous Insufficiency impacts millions worldwide. It is a progressive vascular disease. Leg veins fail to return blood efficiently to the heart. This leads to sustained high venous pressure. Aging, obesity, and sedentary lifestyles drive its prevalence. Advanced CVI causes chronic pain, swelling, and severe skin damage. Debilitating ulcers often develop. Current treatments merely manage symptoms. They do not offer a cure. CVI represents a massive unmet medical need. Its associated long-term costs are high. Patient quality of life suffers immensely.
P-TEV aims to revolutionize CVI treatment. It targets the underlying cause of disease. The therapy replaces diseased segments with functioning veins. The process uses donor-derived venous material. This material undergoes decellularization. It then becomes personalized. The patient's own blood is used in this customization. The result is a patient-specific graft. Surgeons implant this graft. It restores natural venous function. This approach differs from synthetic grafts. It avoids artificial materials. P-TEV restores native biology. It provides a one-time, restorative solution for CVI patients.
Verigraft's P-TEV is now in a pivotal Phase II/III trial. This trial is crucial for market entry. It aims for US and European market approval. The target year for approval is 2028. Trial sites are located across Europe. Spain, the Netherlands, and Poland host these studies. Earlier, Verigraft completed its first-in-man Phase I/II trial. That was a major corporate milestone. The company's clinical development generates robust data. This is key for Advanced Therapy Medicinal Products, or ATMPs. Strong results pave the way for widespread adoption and patient access.
Verigraft secured substantial funding. Existing long-term shareholders injected $10 million. This investment directly supports the pivotal Phase II/III clinical studies. It empowers the company's global expansion efforts. Investment advisors recognize Gothenburg's biotech ecosystem. This environment supports innovative companies. It fosters connections with international investors. Verigraft’s success draws significant international capital. The funding underscores investor confidence in the technology and its market potential.
The CVI market is vast. Projections estimate it will reach $5,951 million by 2034. P-TEV targets this lucrative segment. Its potential as a curative treatment is immense. Beyond CVI, Verigraft explores other applications. It develops personalized arteries. Next-generation tissue engineering is a focus. This includes 3D-bioprinted scaffolds. The company contributes to broader regenerative medicine advancements. Its work received industry accolades. Verigraft coordinates the Eurostars PREPPER project. This project develops 3D-printed arterial grafts. Such initiatives highlight Verigraft's leadership in the field. They demonstrate a commitment to diverse solutions in vascular health.
Verigraft stands at the forefront of medical innovation. Its personalized therapies promise to transform patient care. The P-TEV trial represents a major leap. It offers hope for millions suffering from CVI. The company's vision extends to other vascular challenges. This solidifies its position as a key player in biotechnology. Verigraft redefines the future of regenerative medicine and personalized biological treatments.
Verigraft, a pioneering Swedish biotechnology company, pushes the boundaries of personalized medicine. Its innovative approach targets serious vascular conditions. The company just initiated a pivotal Phase II/III clinical trial. This trial focuses on Chronic Venous Insufficiency, or CVI. It represents a significant step for patients globally.
The core of Verigraft's innovation is P-TEV. This stands for Personalized Tissue-Engineered Vein. P-TEV offers a fully biological transplant. It replaces damaged vein segments. The technology removes the need for lifelong immunosuppression. This factor greatly improves patient recovery. It enhances overall quality of life. The process is scalable. Manufacturing completes within ten days. This makes it clinically feasible for wide application. Ninety-two granted patents protect this groundbreaking method.
Chronic Venous Insufficiency impacts millions worldwide. It is a progressive vascular disease. Leg veins fail to return blood efficiently to the heart. This leads to sustained high venous pressure. Aging, obesity, and sedentary lifestyles drive its prevalence. Advanced CVI causes chronic pain, swelling, and severe skin damage. Debilitating ulcers often develop. Current treatments merely manage symptoms. They do not offer a cure. CVI represents a massive unmet medical need. Its associated long-term costs are high. Patient quality of life suffers immensely.
P-TEV aims to revolutionize CVI treatment. It targets the underlying cause of disease. The therapy replaces diseased segments with functioning veins. The process uses donor-derived venous material. This material undergoes decellularization. It then becomes personalized. The patient's own blood is used in this customization. The result is a patient-specific graft. Surgeons implant this graft. It restores natural venous function. This approach differs from synthetic grafts. It avoids artificial materials. P-TEV restores native biology. It provides a one-time, restorative solution for CVI patients.
Verigraft's P-TEV is now in a pivotal Phase II/III trial. This trial is crucial for market entry. It aims for US and European market approval. The target year for approval is 2028. Trial sites are located across Europe. Spain, the Netherlands, and Poland host these studies. Earlier, Verigraft completed its first-in-man Phase I/II trial. That was a major corporate milestone. The company's clinical development generates robust data. This is key for Advanced Therapy Medicinal Products, or ATMPs. Strong results pave the way for widespread adoption and patient access.
Verigraft secured substantial funding. Existing long-term shareholders injected $10 million. This investment directly supports the pivotal Phase II/III clinical studies. It empowers the company's global expansion efforts. Investment advisors recognize Gothenburg's biotech ecosystem. This environment supports innovative companies. It fosters connections with international investors. Verigraft’s success draws significant international capital. The funding underscores investor confidence in the technology and its market potential.
The CVI market is vast. Projections estimate it will reach $5,951 million by 2034. P-TEV targets this lucrative segment. Its potential as a curative treatment is immense. Beyond CVI, Verigraft explores other applications. It develops personalized arteries. Next-generation tissue engineering is a focus. This includes 3D-bioprinted scaffolds. The company contributes to broader regenerative medicine advancements. Its work received industry accolades. Verigraft coordinates the Eurostars PREPPER project. This project develops 3D-printed arterial grafts. Such initiatives highlight Verigraft's leadership in the field. They demonstrate a commitment to diverse solutions in vascular health.
Verigraft stands at the forefront of medical innovation. Its personalized therapies promise to transform patient care. The P-TEV trial represents a major leap. It offers hope for millions suffering from CVI. The company's vision extends to other vascular challenges. This solidifies its position as a key player in biotechnology. Verigraft redefines the future of regenerative medicine and personalized biological treatments.